- Novocure stated that patients treated with its TTFields therapy simultaneously with atezolizumab, gemcitabine and nab-paclitaxel showed that the disease control rate was at 74.4%.
- In contrast, patients who received only atezolizumab, gemcitabine and nab-paclitaxel had a disease control rate of 48%.
- Among patients receiving TTFields therapy alongside atezolizumab and gem/nab-pac, the objective response rate was 34.6%, while the median overall survival was 9.7 months.
Novocure (NVCR) shares gained nearly 3% in Thursday’s opening trade after the company announced positive topline results in its metastatic pancreatic cancer therapy trial.
Novocure stated that PANOVA-4 met its pre-specified primary endpoint in the Phase 2 trial, achieving a statistically significant improvement in disease control rate. The PANOVA-4 study is a pilot, single-arm study of Tumor Treating Fields (TTFields) concomitant with atezolizumab, gemcitabine, and nab-paclitaxel as first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC).
Retail sentiment on Stocktwits around Novocure trended in the ‘bullish’ territory. NVCR was among the top trending tickers on the platform at the time of writing.
Novocure Therapy Improves Disease Control Rate
Novocure stated that patients treated with its TTFields therapy simultaneously with atezolizumab, gemcitabine and nab-paclitaxel showed that the disease control rate was at 74.4%.
In contrast, patients who received only atezolizumab, gemcitabine and nab-paclitaxel had a disease control rate of 48%.
“The positive results from the PANOVA-4 trial further support the potential of Tumor Treating Fields to improve outcomes in pancreatic cancer,” said Uri Weinberg, Chief Medical and Innovation Officer, Novocure.
Secondary endpoints in PANOVA-4 included objective response rate (ORR) and overall survival (OS). Among patients receiving TTFields therapy alongside atezolizumab and gem/nab-pac, ORR was 34.6%, while median OS was 9.7 months.
Additional secondary endpoints included progression-free survival, one-year survival rate, six-month progression-free survival, duration of response, and incidence of treatment-emergent adverse events.
The company stated that TTFields therapy was well-tolerated, and device-related safety was consistent with prior clinical studies.
What Does Novocure Do?
Novocure is a Switzerland-based company that is currently developing and commercializing its Tumor Treating Fields therapy. Its commercialized products have been approved in certain countries for the treatment of adult patients with glioblastoma, pancreatic cancer, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma.
NVCR stock is down 10% year-to-date and 38% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 22% over the past 12 months, while the Vanguard Small-Cap Growth Index Fund ETF Shares (VBK) is up 18%.
For updates and corrections, email newsroom[at]stocktwits[dot]com.